Sarepta Therapeutics (SRPT) 25.91 $SRPT Catabasis' DMD

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sarepta Therapeutics (SRPT) 25.91 $SRPT

Catabasis' DMD Drug in Phase II Open-Label Extension Study
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:28AM CDT
Catabasis (CATB) initiated an open-label extension for the phase II portion (Part B) of its MoveDMD study on edasalonexent for the treatment of DMD.
BMRN: 100.25 (+0.83), CATB: 4.08 (+0.21), GWPH: 96.11 (+1.79), SRPT: 25.91 (+0.63)

4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 301.83 (+11.90), BMRN: 100.25 (+0.83), SRPT: 25.91 (+0.63), ALXN: 133.50 (+4.90), IBB: 294.07 (+4.63), REGN: 434.00 (+8.88)

Sarepta Therapeutics Announces Common Stock Offering
BusinessWire - Thu Jun 09, 6:00AM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., agreed to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 25.91 (+0.63)

Sarepta Therapeutics Announces Proposed Offering
BusinessWire - Wed Jun 08, 3:19PM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., intends to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 25.91 (+0.63)

Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 301.83 (+11.90), SRPT: 25.91 (+0.63), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), REGN: 434.00 (+8.88), CELG: 114.69 (+2.50)

Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 100.25 (+0.83), SRPT: 25.91 (+0.63), PFE: 37.31 (+0.42), BMY: 76.19 (+1.38)

Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
BusinessWire - Mon Jun 06, 4:40PM CDT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.
SRPT: 25.91 (+0.63)

Why Is Sarepta Therapeutics (SPRT) Stock Down 20% Today?
Ryan McQueeney - Zacks Investment Research - Thu Jun 02, 12:11PM CDT
Shares of Sarepta Therapeutics (SRPT) fell nearly 20% in early morning trading Thursday after new reports suggested that the Food and Drug Administration may force the company to offer its Duchenne muscular dystrophy (DMD) drug to patients at cost.
SRPT: 25.91 (+0.63)

The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 301.83 (+11.90), SRPT: 25.91 (+0.63), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), IONS: 38.01 (+8.82)

Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), SRPT: 25.91 (+0.63), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), IONS: 38.01 (+8.82)

Pre-Market Technical Breakdown Highlights on Biotech Stocks
ACCESSWIRE - Wed Jun 01, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 1, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Gilead Sciences, Baxalta, MannKind, and Sarepta Therapeutics.
GILD: 80.46 (+0.99), SRPT: 25.91 (+0.63), BXLT: 46.02 (-0.18), MNKD: 1.02 (+0.03)

BioMarin Withdraws Kyndrisa Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 6:49AM CDT
BioMarin (BMRN) has withdrawn its regulatory application for Kyndrisa from the EU, following discussions with the EMA's CHMP.
BMRN: 100.25 (+0.83), ANIP: 61.06 (+0.46), SRPT: 25.91 (+0.63), BMY: 76.19 (+1.38)

Why is Sarepta Therapeutics (SRPT) Stock Soaring 20% Today?
Madeleine Johnson - Zacks Investment Research - Wed May 25, 12:35PM CDT
On Wednesday, shares of Sarepta Therapeutics (SRPT) are soaring, up almost 20% in afternoon trading on news that the company announced that the Food & Drug Administration (FDA) has delayed ruling in its drug eteplirsen.
SRPT: 25.91 (+0.63)

FDA delay raises slim hope for muscular dystrophy drug
By MATTHEW PERRONE - AP - Wed May 25, 11:23AM CDT
WASHINGTON (AP) — Federal health regulators will take more time to review a highly-contested drug for muscular dystrophy that has become a flashpoint in the debate over patient access to experimental medicine.
SRPT: 25.91 (+0.63)

Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date
BusinessWire - Wed May 25, 6:00AM CDT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that they are continuing their review and internal discussions related to our pending NDA for eteplirsen and will not be able to complete their work by the Prescription Drug User Fee Act (PDUFA) goal date of May 26, 2016. The FDA has communicated that they will continue to work past the PDUFA goal date and strive to complete their work in as timely a manner as possible.
SRPT: 25.91 (+0.63)

Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
GlobeNewswire - Fri May 20, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of Sarepta Therapeutics.
CYTK: 11.49 (+0.37), SRPT: 25.91 (+0.63)

CORRECTING and REPLACING Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinessWire - Tue May 10, 4:08PM CDT
Please replace the release dated February 2, 2016 with the following corrected version due to multiple revisions.
SRPT: 25.91 (+0.63)

Third Annual BLINGO Raises $200,000 for CureDuchenne
BusinessWire - Fri May 06, 11:19AM CDT
On Saturday, April 30th, CureDuchenne, a national nonprofit that raises awareness and funds for research to find a cure for Duchenne Muscular Dystrophy, hosted a "blinged-out" event at The Logan Hotel--featuring special bingo callers including FOX29 News General Assignment Reporter, Jennaphr Frederick, former Governor Edward G. Rendell, WMMR Preston and Steve show producer, Marisa Magnatta, local sensation John Bolaris, and comedian Joe Conklin in celebration for a cause to help save the lives of those with Duchenne.
SRPT: 25.91 (+0.63)

Sarepta Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 6:24AM CDT
CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Thursday reported a loss of $59.8 million in its first quarter.
SRPT: 25.91 (+0.63)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 22

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 92

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 26

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 11

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 57

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 239

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Laser Photonics CMS Expands Their Market Presence with New Orders

Updated Category News Views 145

Laser Photonics CMS Expands Their Market Presence with New Orders Laser Photonics Corporation (NASDAQ: LASE), a prominent global player in the manufacturing of innovative industrial laser systems, has announced recent progress from its subsidiary, Control Micro Systems (CMS). This exciting development highlights the increasing applications of laser technology in various...

Continue Reading
WuXi Biologics Expands Operations with New Syringe Production Line

Updated Category News Views 221

WuXi Biologics Expands Production Capabilities WuXi Biologics (2269.HK), a renowned global Contract Research, Development, and Manufacturing Organization (CRDMO), is set to strengthen its product capabilities by launching a new sterile filling line designed specifically for prefilled syringes (PFS). This initiative is taking place at WuXi's facility in Leverkusen,...

Continue Reading
Unlocking the Future: SEALSQ's MS6003 Secure Element Launch

Updated Category News Views 232

Revolutionizing Secure Authentication with MS6003 SEALSQ Corp (NASDAQ: LAES), a leader in semiconductor innovation, has recently announced a significant addition to its product portfolio: the MS6003 secure element chip. This state-of-the-art chip is equipped with a preloaded FIDO2 application, marking a pivotal step towards enhancing passwordless authentication in an era...

Continue Reading
Boeing's Outlook Brightens Amid Trade Deal Backlogs

Updated Category News Views 197

Boeing's Promising Trade Developments Boeing Co.'s earnings call showcased a significant shift in the global trade landscape, influenced by recent agreements during the Trump administration. This transition is likely to ease tariff pressures, providing vital support for the aerospace giant’s impressive backlog that currently exceeds $600 billion. The Financial Snapshot...

Continue Reading
Supreme Court's Decision on Appian vs. Pegasystems Verdict Case

Updated Category News Views 407

Supreme Court to Review Appian's Petition Against Pegasystems The Supreme Court of Virginia has decided to hear a significant legal case involving Appian and Pegasystems, Inc., which revolves around a staggering judgment amounting to $2.036 billion. This case is crucial as it pertains to the protection of intellectual property and trade secrets in the tech industry....

Continue Reading